Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur

Inclusion criteria

• Males and females age 18 years or more
• X-ray confirming basicervical, pertrochanteric or subtrochanteric femur fracture and planning operation with DHS or PFN.
• Subjects must have 7 or more points in the Hindsøes test.

Exclusion criteria

• Subjects where spinal anaesthesia cannot be applied.
• Subject in Plavix® treatment seven days before admission to the hospital.
• Subjects with extracapsular hip fracture due to bone metastasis.
• Subjects with a BMI over 30.
• Subjects under 45 kg.
• Subjects who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 2 weeks prior admission to the hospital.
• Substance or alcohol abuse, or subjects who, in the opinion of the investigator have demonstrated addictive or substance abuse behavior.
• Untreated depression or other psychiatric disorder in such a way that participation in the study may in the opinion of the investigator pos an unacceptable risk to the subject.
• Dermatological disorder at any relevant patch application site.
• Any contraindications listed in the Summary of Product Characteristics for Norspan®, OxyNorm® and OxyContin®.
• Patient does not tolerate oxynorm.
• User of wheelchair.
• Daily use of morphine before hospitalization.
• More than one fracture. Patients with myasthenia gravis. Patients with severe respiratory function. Patients know need re-operation women of childbearing potential must have a negative pregnancy test and be non-lactating